Abstract 132P
Background
Oncogenic mutation p53(Y220C) is the ninth most common mutation of the p53 protein. Mutation Y220C creates an expanded surface pocket in the DNA-binding domain of p53, due to which the protein is rapidly denatured under physiological conditions. This also negatively affects the effectiveness of p53-dependent signaling and leads to tumor development. In this work, new indazole derivatives were investigated as modulators of mutant p53 activity. We found that the compounds studied were able to initiate an anti-tumor cellular response by activating mutant p53(Y220C).
Methods
Immunocytochemical analysis (ICC) was performed to test the hypothesis that the mutant protein p53(Y220C) can restore its native-like conformation and get reactivated upon interaction with the compounds. The degree of p53 activation was evaluated, and the protein localization in HUH7 p53(Y220C) human hepatocarcinoma cells was determined upon treatment with indazole derivatives.
Results
During the immunocytochemical analysis, images obtained were analyzed using the ImageJ software, and the values of p53 signal intensity were calculated. We found that in comparison with control untreated cells, in samples treated with indazole derivatives increased in levels of p53 were observed mainly in the nucleus, which indicates its activation.
Conclusions
The results of the immunocytochemical analysis demonstrated that indazole derivatives specifically activate mutant p53(Y220C) protein. The compounds represent a promising basis for the development of selective activators not only for Y220C, but also for other mutant forms of p53. The work was funded by grant from the Russian Science Foundation 22-24-20034 and supported by the Kazan Federal University Strategic Academic Leadership Program (PRIORITY-2030).
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
The work was funded by grant from the Russian Science Foundation 22-24-20034 and supported by the Kazan Federal University Strategic Academic Leadership Program (PRIORITY-2030).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
158P - Enhancing the communication of genomic results: Understanding patient and clinician perspectives
Presenter: Eleanor Johnston
Session: Cocktail & Poster Display session
Resources:
Abstract
159P - Precision medicine-based platform to guide the treatment of EML4-ALK fusion lung cancers and other NSCLC
Presenter: Nathan Merrill
Session: Cocktail & Poster Display session
Resources:
Abstract
160P - CICLADES-CE study: Genomic signatures detected in DNA from FFPE samples of patients with advanced or metastatic breast cancers treated with anti-aromatase and CDK4/6 inhibitors
Presenter: Margaux BETZ
Session: Cocktail & Poster Display session
Resources:
Abstract
161P - PDL1 expression and its relation to EML4-ALK gene variants in metastatic lung adenocarcinoma: A single-center real-world experience
Presenter: Santhosh Meedimale
Session: Cocktail & Poster Display session
Resources:
Abstract
163P - Impact of genomic sequencing data on treatment decisions in advanced breast cancer (ABC)
Presenter: Sviatoslav Chekhun
Session: Cocktail & Poster Display session
Resources:
Abstract
164P - Clinical utility of comprehensive molecular profiling tests for advanced gastrointestinal tumors
Presenter: Alexandra Lebedeva
Session: Cocktail & Poster Display session
Resources:
Abstract
165P - Evaluation of the mutational profile in patients with metastatic non-small cell lung carcinoma diagnosed in a tertiary hospital which was performed by NGS method
Presenter: Kankan Deka
Session: Cocktail & Poster Display session
Resources:
Abstract
166P - Targeted next-generation sequencing as reliable detection of genetic profile for cancer treatment to guide oncologists in Pakistan
Presenter: Zeeshan Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
167P - Molecular analysis of gastrointestinal stromal tumor (GIST): The experience of Regina Elena National Cancer Institute
Presenter: Andrea Torchia
Session: Cocktail & Poster Display session
Resources:
Abstract
168P - Usefulness of liquid biopsy in the management of patients with advanced or metastatic pancreatic cancer
Presenter: Jorge Iranzo Barreira
Session: Cocktail & Poster Display session
Resources:
Abstract